Longboard Pharmaceuticals — Investor Presentation (March 2024)
41 slides from Longboard Pharmaceuticals's investor presentation, Mar 12, 2024
Slide 1: Corporate Presentation March 12, 2024
Corporate Presentation March 12, 2024 Exhibit 99.2
Slide 2: Forward-Looking Statements and Other Legal Notices
Forward-Looking Statements and Other Legal Notices This presentation contains forward-looking statements about Longboard Pharmaceuticals, Inc. (“we,” “Longboard” or the “Company”), including statements regarding: our vision; commercial opportunities and analogs; anticipated milestones and timing; th
Slide 3: Our Vision is Backed by 20+ Years of World Class GPCR Research
Our Vision is Backed by 20+ Years of World Class GPCR Research Longboard Thesis Vision A world where devastating neurological conditions are no longer devastating 3 Longboard Pharmaceuticals Differentiated & innovative clinical approaches Relevant M&A analogs JAZZ - GW $7.2B PFE - ARNA $6.7B UCB - Z
Slide 4: Longboard's Potentially Best-in-Class Product Candidates
Longboard’s Potentially Best-in-Class Product Candidates* * Through a License Agreement with Arena ** Through a Royalty Purchase Agreement with Arena Definitions: DEEs=developmental and epileptic encephalopathies; S1P=sphingosine 1-phosphate; PK=pharmacokinetics; PD=pharmacodynamics; EEG=electroence
Slide 5: Developmental & Epileptic Encephalopathies (DEE) Landscape
Developmental & Epileptic Encephalopathies (DEE) Landscape
Slide 6: DEE Prevalence: 4 Syndromes Have Approved Therapies; 20+ Have None
The prevalence of all "Other DEEs" could exceed the total of the “Approved 4” combined 4 DEE Syndromes Have Approved Therapies; 20+ Have None Sources: Dravet Syndrome Foundation, LGS Foundation Definitions: LGS = Lennox-Gastaut Syndrome, CDD = CDKL5 Deficiency Disorder, TSC = Tuberous Sclerosis Comp
Slide 7: Unmet Needs for Patients with Other DEEs
Unmet Needs for Patients with Other DEEs Among those who treat patients with other DEEs (not “Approved 4”) Surveyed HCPs Report a Need for More Effective and Safer Anti-Seizure Medications for Other DEEs Mean # of Seizures Per Week Mean # of ASMs Per Patient Dravet 12 3.4 LGS 19 3.5 TSC 6 3.0 CDD 13
Slide 8: Nearly All Surveyed HCPs Treat Patients with All DEE Diagnoses
Nearly All Surveyed HCPs Treat Patients with All DEE Diagnoses; Collectively, the Number of “Other DEEs” is Significant DEE Types Treated in the Past 12 Months Percent of Patients with DEE Type Based on Longboard sponsored third-party qualitative and qualitative market research studies involving phy
Slide 9: Surveyed HCPs Prefer a Highly Selective 5-HT2C Agonist with Broad DEE Indication
Surveyed HCPs Prefer a Highly Selective 5-HT2C Agonist* with a Broad DEE Indication, and Anticipate This Will Positively Impact DEE Patients’ Treatment Options 80% Anticipate a Broad DEE Indication will have a positive impact on treatment options for patients 0% Believe it would have a negative impa
Slide 10: DEE Indications Represent a $6B Total US + EU Market Opportunity
1) Longboard and third-party research 2022 – projections for 2040 for US + EU4/UK, 2) UCB FY 2023 Earnings Release and presentation dated February 28, 2024, 3) Jazz Pharmaceuticals FY 2023 Earnings Release dated February 28, 2024, 4) Jazz Corporate Overview August 2023 DEE Indications Represent a $6
Slide 11: Bexicaserin (LP352) Potential Best-in-Class 5-HT2C Superagonist
Bexicaserin (LP352) Potential Best-in-Class 5-HT2C Superagonist - Entering a Ph 3 Program with the Goal of Treating a Broad Range of DEEs
Slide 12: The Potential of Bexicaserin (LP352)
The Potential of Bexicaserin (LP352) *Radioligand binding assays assessing >150 targets showed significant affinity only to 5-HT2C receptors ** Based on first two cohorts from the 102 study ***Composition of matter through 2036 with potential for PTE / PTA (2041) Definitions: PAH = pulmonary arteria
Slide 13: Bexicaserin Designed to be Next-Generation 5-HT2C with Greater Selectivity
1 Third party study previously commissioned by Arena, 2 BELVIQ FDA approved prescribing information 06/2012; Note: The above table is for illustrative purposes only and is not a head-to-head comparison. Differences exist between in vitro study designs and methodologies, and caution should be exercis
Slide 14: PACIFIC Study Topline Data
PACIFIC Study Topline Data LONGBOARD
Slide 15: Bexicaserin Ph 1b/2a PACIFIC Study in Participants with DEEs
6 mg 9 mg 12 mg Participant remains on 6, 9 or 12 mg based on tolerability during up-titration 5 Wks Screening Period 30 Days Follow-up Period Randomization & Up-Titration Days 1-15 Maintenance* Days 16-75 Down- Titration Days 76- 80/90** Bexicaserin (LP352) Ph 1b/2a PACIFIC Study in Participants wi
Slide 16: PACIFIC Study Enrollment Summary
PACIFIC Study Enrollment Summary 52 Participants randomized Diagnosis 42 US 10 AUS Adult/Pediatric participants Range: 12-55 Mean: 24.3 / Median: 23.0 40 Adult (18+) 12 Peds (12-17) Dravet: 4 LGS: 29 Other DEE*: 19 *The diagnosis was at time of screening for PACIFIC and is subject to further refinem
Slide 17: Diagnostic Eligibility Criteria: Dravet, LGS and Other DEEs
Diagnostic Eligibility Criteria: Dravet Syndrome, Lennox-Gastaut Syndrome (LGS) and Other DEEs *Abnormal inter-ictal EEG background activity with inter-ictal slow spike-and-wave pattern ≤2.5 Hz or inter-ictal generalized paroxysmal fast activity All participants: Treatment-resistant countable motor
Slide 18: Bexicaserin Has the Potential to Change the DEE Landscape
Bexicaserin Has the Potential to Change the DEE Landscape *Not statistically significant **Composition of matter through 2036 with potential for PTE / PTA (2041) Bexicaserin provides the cornerstone to potentially build a world-class epilepsy franchise Studies to date highlight bexicaserin as potent
Slide 19: Topline Participant Disposition & Safety Results Summary
Topline Participant Disposition & Safety Results Summary
Slide 20: Demographics, Baseline Characteristics & Concomitant Medications
Demographics, Baseline Characteristics & Concomitant Medications Parameter n(%) Statistics Bexicaserin (N=43) Placebo (N=9) Overall (N=52) Age (Years) Mean 23.8 26.7 24.3 Standard Deviation 9.62 7.73 9.31 Median 23.0 23.0 23.0 Min, Max 12, 55 19, 41 12, 55 Sex Male 21 (48.8) 7 (77.8) 28 (53.8) Femal
Slide 21: Participant Disposition
Participant Disposition n(%) Overall Dravet Syndrome Lennox-Gastaut Syndrome (LGS) LGS DEE Other Bexicaserin Placebo Bexicaserin Placebo Bexicaserin Placebo Bexicaserin Placebo Safety Set 43 (100) 9 (100) 4 (9.3) 0 24 (55.8) 5 (55.6) 15 (34.9) 4 (44.4) Full Analysis Set 35 (81.4) 9 (100) 3 (7.0) 0 1
Slide 22: Safety Results Summary
Safety Results Summary n(%) Bexicaserin (LP352) (N=43) Placebo (N=9) Overall (N=52) Participants with any TEAEs 35 (81.4) 8 (88.9) 43 (82.7) Drug-Related TEAEs 28 (65.1) 3 (33.3) 31 (59.6) TEAEs Leading to Discontinuation 9 (20.9) 0 9 (17.3) TEAEs Leading to Discontinuation (Titration) 7 (16.3) 0 7
Slide 23: Topline Efficacy Results
Topline Efficacy Results LONGBOARD
Slide 24: Bexicaserin Achieved Median Seizure Reduction of 59.8% vs 17.4% Placebo
Bexicaserin Achieved Median Seizure Reduction of 59.8% in Countable Motor Seizures Compared to 17.4% for Placebo Across the DEE Study Population Bexicaserin Achieved Placebo-Adjusted Mean Seizure Reduction of 52.0% (not the primary efficacy endpoint)
Slide 25: Median Seizure Reduction Across Dravet, LGS, DEE Other Cohorts
Bexicaserin Achieved Median Seizure* Reduction Across Dravet, LGS, DEE Other Cohorts Bexicaserin (LP352) Placebo Δ 33.4% Δ 33.3% *Countable Motor Seizures
Slide 26: PACIFIC Results Pave the Way for Global Phase 3 Program
PACIFIC Results Pave the Way for Global Phase 3 Program Bexicaserin (LP352) achieved a median percent reduction from baseline in seizure frequency during the treatment period of: 59.8% in broad DEE population (42.4% placebo-adjusted) 74.6% in Dravet cohort 50.8% in LGS cohort (33.4% placebo-adjusted
Slide 27: Bexicaserin Phase 3 Global Program - Potential Paths Forward
Bexicaserin Phase 3 Global Program - Potential Paths Forward Subject to Discussion with Regulatory Agencies Planned Study Parameters: Primary Endpoint: Reduction in Countable Motor Seizures Ages: ≥ 2 to ≤ 65 yrs old (weight-based dosing for pts of lower weight/age) Sites: ~80 sites across the US, AU
Slide 28: Commercial Opportunity for Bexicaserin (LP352)
Commercial Opportunity for Bexicaserin (LP352)
Slide 29: Potential Best-in-Class Profile Provides Multiple Ways to Win
Potential Best-in-Class Profile Provides Multiple “Ways to Win” $6B Total Addressable Market Capture market share in “Approved 4” with best-in-class profile (safety, efficacy, burden) Broaden market in “Approved 4” DEEs with preferred safety and burden profile Expand market to address significant un
Slide 30: Quantitative and Qualitative HCP Research
Quantitative HCP Research 100 Physicians Objective: Validating Unmet Needs And LP352 Potential Criteria: Board Certified HCPs specializing in Neurology or Epileptology Treat at least 20 patients with DEEs in the past 12 months Familiar with Fintepla and Epidiolex Note: Most participants have some cl
Slide 31: Influence on ASM Decisions
Influence on ASM Decisions When allocating 100 points across factors If I see a patient with epilepsy and give them enough valium, they’ll be seizure free, but then they'll be sleeping all day. That’s not quality of life. So, we must find the cocktail that gives them the best seizure control with th
Slide 32: LP659 Centrally Acting, Highly Selective S1P Receptor Modulator
LP659 Centrally Acting, Highly Selective Sphingosine-1-Phosphate (S1P) Receptor Modulator Targeting Multiple Neurological Diseases
Slide 33: LP659 Potential Best-in-Class S1P Receptor Modulator
LP659 Potential Best-in-Class S1P Receptor Modulator with Broad Applicability STRONG SCIENTIFIC RATIONALE COMMERCIALLY ATTRACTIVE S1P receptor modulators have generated billions of dollars of revenues in CNS indications Designed to potentially address multiple neurological disorders Opportunity for
Slide 34: S1PR1 Modulation Selectively Reduces Migration of Lymphocytes
S1PR1 Modulation Selectively Reduces Migration of Lymphocytes From Lymph Nodes Functionally antagonizes S1PR1 by inducing receptor internalization and degradation, disrupting normal lymphocyte subset egress Decreases release of inflammatory cytokines and reduce organ/tissue damage Maintains immune s
Slide 35: LP659 Next Generation Centrally-Acting S1PR1 Agonist
LP659 Designed to be a Potentially Next Generation Centrally-Acting S1PR1 Agonist with Greater Selectivity and Internalization-Biased Signaling LP659 selectivity may limit off-target effects associated with currently approved S1P receptor modulators Greatest selectivity towards S1PR1 over S1PR5 Most
Slide 36: Modulation of Immune Tolerance Drives Efficacy by LP659
Modulation of Immune Tolerance Drives Efficacy by LP659 LP659 potency in vivo parallels T and B cell lowering potential Proportion of Tregs over total CD3+ cells is significantly increased by LP659 No significant effects on NK and monocyte frequencies Internal data on file
Slide 37: LP659 Ameliorated Disease Phenotypes in Multiple Preclinical Models
LP659 Ameliorated Disease Phenotypes in Multiple Preclinical Models Disease / MoA Autoimmune, CNS involvement Autoimmune, CNS involvement Autoimmune, PNS involvement Autoimmune, PNS involvement Neuro Degenerative Model Induced Induced Induced Induced Genetic Species Rat Mouse Rat Rat Human iPSC Dosi
Slide 38: LP659: Phase 1 Single-Ascending Dose (SAD) Study Objectives
LP659: Phase 1 Single-Ascending Dose (SAD) Study Objectives First-In-Human, Randomized, Double Blind, Placebo Controlled, SAD Study to Assess the Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of LP659 in up to 48 Adult Healthy Volunteers Key Study Objectives: Assess the safety and tolera
Slide 39: Longboard Indication Assessment Process
Longboard Indication Assessment Process Scientific Rationale Commercial & Development Criteria Etiology Pathophysiology Approved SoC Preclinical Studies Patient Advocacy & Recruitment Degree of Unmet Need Speed of Clinical Development Clinical Trial Feasibility Competitive Headroom Pricing Potential
Slide 40: Financial Summary & Upcoming Milestones
Financial Summary & Upcoming Milestones Multiple clinical and preclinical studies in process to further support the development of bexicaserin & LP659 Cash, Cash Equivalents & Investments $272.4 million As of January 31,2024 Shares Outstanding 36.0 million As of March 8, 2024 Full-Year 2023 Operatin
Slide 41: Thank you
Thank you Nasdaq: LBPH [email protected]
Longboard Pharmaceuticals — Investor Presentation (March 2024) on 6ix